Last mentioned: Feb 26, 2026
Trulieve Cannabis and MannKind reported divergent fourth-quarter results, with Trulieve beating earnings expectations despite a revenue miss, while MannKind saw a significant revenue surge that failed to translate into an EPS beat. These results highlight the ongoing tension between top-line growth and operational profitability in the cannabis and biopharma sectors.
Trulieve Cannabis and MannKind reported divergent Q4 results, with Trulieve showing improved bottom-line resilience despite revenue misses, while MannKind delivered a significant revenue beat offset by an earnings-per-share shortfall. These results highlight the ongoing tension between operational scaling and profitability in the cannabis and specialty pharmaceutical sectors.
Trulieve Cannabis and MannKind reported mixed fourth-quarter results, with Trulieve beating earnings expectations despite a revenue miss. Meanwhile, MannKind delivered a significant revenue beat alongside an earnings shortfall, highlighting the divergent growth trajectories in the cannabis and biopharmaceutical sectors.